The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells
Open Access
- 12 December 2023
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 100, 104900
Abstract
No abstract availableKeywords
Funding Information
- California Institute for Regenerative Medicine (CLIN2-09444)
- National Center for Advancing Translational Sciences
- Clinical and Translational Science Institute, University of California, Los Angeles (UL1TR001881)
This publication has 40 references indexed in Scilit:
- The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Modern Age Pathology of Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertensionHistopathology, 2012
- Pulmonary Lymphoid Neogenesis in Idiopathic Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Progressive Right Ventricular Dysfunction in Patients With Pulmonary Arterial Hypertension Responding to TherapyJACC, 2011
- Regulatory T Cells Limit Vascular Endothelial Injury and Prevent Pulmonary HypertensionCirculation Research, 2011
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cureAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Interleukin-6 Overexpression Induces Pulmonary HypertensionCirculation Research, 2009
- Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertensionEuropean Heart Journal, 2007